Plus Therapeutics Reports Granting of Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)

Plus Therapeutics (Nasdaq: PSTV) granted inducement equity awards to Eric J Daniels, M.D., who joined as Chief Development Officer on April 20, 2026.

Rhea-AI Summary

Plus Therapeutics (Nasdaq: PSTV) granted inducement equity awards to Eric J Daniels, M.D., who joined as Chief Development Officer on April 20, 2026. The awards include 20,000 stock options and 20,000 restricted stock units (RSUs), approved under Nasdaq Rule 5635(c)(4).

Options have a 10-year term with an exercise price of $7.30 (fair market value at grant). Options vest over four years; RSUs vest over three years, each subject to continued service.

Positive

• Granted 20,000 stock options and 20,000 RSUs to new Chief Development Officer
• Options carry a 10-year term with a $7.30 exercise price
• Options vest over four years; RSUs vest over three years, supporting retention
• Awards approved under Nasdaq Rule 5635(c)(4), meeting listing requirements

Negative

• None.

Argus Apr 23 session

-4.46% close to close Open Argus

Details

News Market Reaction – PSTV

On Apr 23, the first trading day after this news, PSTV closed 4.46% below the previous close.

Data tracked by StockTitan Argus for the Apr 23 session.

Key Figures

Stock options granted: 20,000 options RSUs granted: 20,000 RSUs Option exercise price: $7.30 +5 more

Stock options granted

20,000 options

Inducement award under 2015 New Employee Incentive Plan

RSUs granted

20,000 RSUs

Inducement award to new Chief Development Officer

Option exercise price

$7.30

Equal to fair market value on April 20, 2026

Option term

10 years

Tenor of inducement stock options

Initial option vesting

25%

Vests on first anniversary of April 20, 2026

Ongoing option vesting

1/36 per month

Monthly vesting following first-year cliff, over remaining term

Initial RSU vesting

1/3 of RSUs

Vests first of quarter after first anniversary

Remaining RSU vesting

Over 8 quarters

Ratable vesting of remaining RSUs over next eight quarters

Historical Context

5 past events · Latest: Apr 21

5 events

1. Apr 21

   Nasdaq compliance

   24h Move

   -2.2%

   Regained compliance with Nasdaq minimum bid price listing requirement.

2. Apr 15

   Executive appointment

   24h Move

   +4.0%

   Appointed VP of Value Strategy & HEOR with related inducement equity grants.

3. Apr 09

   Chief Development Officer hire

   24h Move

   +23.7%

   Named Eric J. Daniels as CDO to advance CNS radiopharmaceutical pipeline.

4. Apr 08

   Orphan designation

   24h Move

   +8.6%

   FDA Orphan Drug Designation for REYOBIQ in pediatric malignant gliomas.

5. Apr 07

   Reimbursement catalyst

   24h Move

   -12.3%

   Received AMA PLA CPT code for CNSide CSF tumor cell enumeration test.

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

Key Terms

restricted stock units, rsus, exercise price, nasdaq rule 5635(c)(4), +2 more

6 terms

restricted stock units financial

"The inducement awards consist of options to purchase 20,000 shares... and 20,000 restricted stock units"

Restricted stock units are a type of company reward where employees are promised shares of stock, but they only fully own these shares after meeting certain conditions, like staying with the company for a set time. They matter because they can become valuable assets and are often used to motivate employees to help the company succeed.

rsus financial

"Each RSU represents a contingent right to receive one share of the Company’s common stock"

RSUs, or restricted stock units, are a form of company shares given to employees as part of their compensation. They are typically awarded with certain restrictions, such as a waiting period before they can be fully owned or sold, similar to earning a gift that becomes fully yours over time. For investors, RSUs can impact a company's stock offerings and reflect how much the company relies on stock-based incentives to attract and retain talent.

exercise price financial

"The options have a 10-year term and an exercise price equal to $7.30"

The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.

nasdaq rule 5635(c)(4) regulatory

"approved by the Compensation Committee... as required by Nasdaq Rule 5635(c)(4)"

NASDAQ Rule 5635(c)(4) is a listing standard that requires a company to obtain shareholder approval before issuing a substantial number of new shares or convertible securities in certain financing or insider-related transactions that would materially dilute existing holders. It matters to investors because the vote gives shareholders a check on deals that could significantly change ownership stakes or voting power—like a homeowners’ association approving a major renovation that affects the whole neighborhood’s value.

equity awards financial

"2015 New Employee Incentive Plan, as amended, which provides for the granting of equity awards"

Equity awards are payments to employees or directors made in the form of company stock or rights to buy stock later, serving as a way to share ownership rather than cash. For investors, they matter because they align staff incentives with company performance, can increase the number of shares outstanding over time (which can reduce each share’s claim on profits), and create compensation costs that affect reported earnings.

inducement awards financial

"announces that it has granted inducement awards to Eric J Daniels, M.D."

Inducement awards are special bonuses given to new employees to encourage them to join a company, often in the form of stock or money. They matter because they can motivate talented people to choose one company over another and help align their success with the company's growth. Think of it like a signing bonus to seal the deal.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

HOUSTON, April 22, 2026 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (Nasdaq: PSTV) (the “Company”), a healthcare company developing and commercializing precision diagnostics and radiopharmaceuticals for central nervous system (CNS) cancers, today announces that it has granted inducement awards to Eric J Daniels, M.D., its new Chief Development Officer who joined the Company on April 20, 2026.

The awards were granted on April 20, 2026 under the Company’s 2015 New Employee Incentive Plan, as amended, which provides for the granting of equity awards to new employees as an inducement to join the Company. The inducement awards consist of options to purchase 20,000 shares of the Company common stock and 20,000 restricted stock units (“RSUs”).

The options have a 10-year term and an exercise price equal to $7.30, the fair market value of the Company’s common stock on the date of grant. The options vest over a four-year period, with 25% of the shares subject to the options vesting on the first anniversary of the vesting commencement date of April 20, 2026, and 1/36^th vesting on each monthly anniversary thereafter, subject to Dr. Daniels’ continued service with the Company through each applicable vesting date.

Each RSU represents a contingent right to receive one share of the Company’s common stock and there is no exercise price associated with the RSUs granted thereunder. The RSUs vest over a three-year period, with 1/3 vesting on the first of the quarter immediately following the first anniversary of the grant date, and the remaining RSUs vesting ratably over the next 8 quarters, subject to Dr. Daniels’ continued service with the Company through each applicable vesting date.

The awards were approved by the Compensation Committee of the Company’s board of directors, as required by Nasdaq Rule 5635(c)(4), and were granted as an inducement material to Dr. Daniels entering into employment with the Company in accordance with Nasdaq Rule 5635(c)(4).

About Plus Therapeutics

Headquartered in Houston, Texas, Plus Therapeutics, Inc. is a clinical-stage pharmaceutical company developing targeted radiotherapeutics for difficult-to-treat cancers of the central nervous system with the potential to enhance clinical outcomes. Combining image-guided local beta radiation and targeted drug delivery approaches, the Company is advancing a pipeline of product candidates with lead programs in leptomeningeal metastases (LM) and recurrent glioblastoma (GBM). The Company has built a supply chain through strategic partnerships that enable the development, manufacturing and future potential commercialization of its products.

Investor Contact
CORE IR
investor@plustherapeutics.com

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What equity awards did Plus Therapeutics (PSTV) grant to its new CDO on April 20, 2026?

The company granted 20,000 options and 20,000 RSUs to the new CDO. According to the company, options have a 10-year term and an exercise price of $7.30 set at grant.

How do the options and RSUs granted by PSTV vest for the new Chief Development Officer?

Options vest over a four-year schedule with 25% after one year then monthly vesting. According to the company, RSUs vest over three years across quarterly installments.

Does Plus Therapeutics (PSTV) state the exercise price for the options granted on April 20, 2026?

Yes. The exercise price is $7.30, equal to the fair market value on the grant date. According to the company, that price applies to the full 10-year option term.

Were the inducement awards to PSTV's new CDO approved in line with Nasdaq rules?

Yes. The awards were approved by the compensation committee as required under Nasdaq Rule 5635(c)(4). According to the company, the grants were made as an inducement to join.

How many shares could be issued by PSTV if all granted awards to the new CDO vest and options are exercised?

Up to 40,000 shares could be issued: 20,000 from RSUs and 20,000 from exercised options. According to the company, issuance is subject to vesting and exercise conditions.